Is CNS Pharmaceuticals, Inc. (CNSP) a Buy, Sell, or Hold?
NASDAQ : CNSP
CNS Pharmaceuticals, Inc.
$5.38 USD
$0.14 (2.77%)
- Volume
- 1.97K
- Average Volume
- 1.43M
- Market Capitalization
- $7.86M
- P/E Ratio
- -0.18
- Dividend Yield
- 0.00%
- Price Target
- $0.50
- Year High
- $10.59
- Year Low
- $1.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.88
Company Overview
NASDAQ
Rami Levin
Biotechnology
Healthcare
CNSP
8
US
USD
Liquidity Metrics
3.29
0.88
0.88
0.64
0.00
Sales & Valuation
-$
0.00
51.45
-0.52
-22.54
Profitability
-$35.75
-$15.85M
0.00%
0.00%
-238.69%
-354.30%
P/E Metrics
-0.18
0.00
0.00
Analyst Price Target & Rating
$0.50
$0.50
$0.50
2/5
4 Analysts
976.00%
Financial Health Scores
-42.44
1/9
-$531.4K
$4.65M
$4.58M
-$16.47M
Key Metrics (TTM)
$5.14M
0.00
-0.31
0.88
-238.69%
-5485.47%
-453.19%
-193.86%
-2067446 days
Company Executives
| Name | Title |
|---|---|
| Steve O'Loughlin | Chief Financial Officer |
| Dylan Wenke | Chief Business Officer |
| E. Lynne Kelley | Chief Medical Officer |
| Christopher S. Downs FP&A | Senior Vice President of Finance |
| Rami Levin | Chief Executive Officer, President & Director |
| Eric Faulkner | Chief Technology Officer |
Poll Results
No votes yet today — be the first to share your view!
About CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Stock
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative ... partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
2026-06-08 09:15:00
Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment. Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company's recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation.
2026-05-20 09:02:00
Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
2026-05-14 11:39:27
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story.
2026-05-14 08:00:00
Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287 New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting the Company's ongoing strategic transformation and execution progress. The first quarter of 2026 marked the beginning of a significant strategic shift for CNS Pharmaceuticals, including the appointment of a new Chief Executive Officer and executive leadership team, the launch of a new corporate strategy, the repositioning of the Company toward an acquisition-driven growth strategy focused on differentiated clinical-stage assets in neurology and oncology and the decision to seek out-licensing opportunities for its legacy glioblastoma multiforme programs, Berubicin and TPI-287.
Frequently Asked Questions
-
What is the current CNS Pharmaceuticals, Inc. (CNSP) stock price?
-
CNS Pharmaceuticals, Inc.(NASDAQ:CNSP) stock price is $5.38 in the last trading session. During the trading session, CNSP stock reached the peak price of $10.588 while $1.9 was the lowest point it dropped to. The percentage change in CNSP stock occurred in the recent session was 2.77% while the dollar amount for the price change in CNSP stock was $0.14.
-
CNSP's industry and sector of operation?
-
The NASDAQ listed CNSP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CNSP?
-
Steve O'Loughlin | Chief Financial Officer
Dylan Wenke | Chief Business Officer
E. Lynne Kelley | Chief Medical Officer
Christopher S. Downs FP&A | Senior Vice President of Finance
Rami Levin | Chief Executive Officer, President & Director -
How many employees does CNSP have?
-
Number of CNSP employees currently stands at 8. CNSP operates from 2100 West Loop South, Houston, TX 77027, US.
-
Link for CNSP official website?
-
Official Website of CNSP is: https://www.cnspharma.com
-
How do I contact CNSP?
-
CNSP could be contacted at phone #800 946 9185 and can also be accessed through its website. CNSP operates from 2100 West Loop South, Houston, TX 77027, US.
-
How many shares of CNSP are traded daily?
-
The average number of CNSP shares traded daily for last 3 months was 1.43M.
-
What is the market cap of CNSP currently?
-
The market value of CNSP currently stands at $7.86M with its latest stock price at $5.38